

Francois Gueyffier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7143453/publications.pdf>

Version: 2024-02-01

105
papers

7,099
citations

126708

33
h-index

56606

83
g-index

119
all docs

119
docs citations

119
times ranked

9174
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. <i>Lancet, The</i> , 2000, 355, 865-872.	6.3	1,136
2	Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2011, 343, d4169-d4169.	2.4	631
3	Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 1999, 353, 793-796.	6.3	593
4	Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. <i>Intensive Care Medicine</i> , 2006, 32, 1175-1183.	3.9	442
5	Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men. <i>Annals of Internal Medicine</i> , 1997, 126, 761.	2.0	307
6	Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. <i>Critical Care</i> , 2011, 15, R99.	2.5	263
7	J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data. <i>Annals of Internal Medicine</i> , 2002, 136, 438.	2.0	253
8	Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome. <i>Hypertension</i> , 2005, 45, 907-913.	1.3	253
9	Meta-analysis of continuous outcomes combining individual patient data and aggregate data. <i>Statistics in Medicine</i> , 2008, 27, 1870-1893.	0.8	222
10	Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. <i>PLoS Medicine</i> , 2012, 9, e1001204.	3.9	217
11	A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2001, 323, 75-81.	2.4	216
12	Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. <i>Journal of Hypertension</i> , 2010, 28, 1366-1372.	0.3	160
13	Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. <i>Journal of Hypertension</i> , 2002, 20, 145-151.	0.3	136
14	Pharmacotherapy for mild hypertension. <i>The Cochrane Library</i> , 2014, 2014, CD006742.	1.5	129
15	Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1413-1431.	1.4	120
16	Severe myoclonic epilepsy in infancy: A systematic review and a meta-analysis of individual patient data. <i>Epilepsia</i> , 2008, 49, 343-348.	2.6	119
17	Asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005 randomized trial. <i>British Journal of Haematology</i> , 2011, 153, 58-65.	1.2	118
18	Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies. <i>JAMA Ophthalmology</i> , 2014, 132, 1317.	1.4	108

#	ARTICLE	IF	CITATIONS
19	Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 52.	0.7	106
20	Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning. <i>Statistics in Medicine</i> , 2020, 39, 2115-2137.	0.8	90
21	Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. <i>Statistics in Medicine</i> , 2013, 32, 2747-2766.	0.8	83
22	Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. <i>Diabetes and Metabolism</i> , 2017, 43, 48-58.	1.4	83
23	Cognitive Therapy versus Rogerian Supportive Therapy in Borderline Personality Disorder. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 307-316.	4.0	82
24	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. <i>European Journal of Heart Failure</i> , 2014, 16, 76-85.	2.9	70
25	Individual patient data meta-analysis of survival data using Poisson regression models. <i>BMC Medical Research Methodology</i> , 2012, 12, 34.	1.4	66
26	Standard requirements for GCP-compliant data management in multinational clinical trials. <i>Trials</i> , 2011, 12, 85.	0.7	61
27	Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. <i>BMJ</i> , 2015, 350, h1088-h1088.	3.0	51
28	Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. <i>Trials</i> , 2010, 11, 79.	0.7	45
29	The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 142.	1.2	43
30	Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach. <i>AAPS Journal</i> , 2013, 15, 1242-1252.	2.2	42
31	Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. <i>BMC Endocrine Disorders</i> , 2016, 16, 39.	0.9	41
32	Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke?. <i>Journal of Hypertension</i> , 2007, 25, 1543-1553.	0.3	35
33	Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. <i>Antiviral Research</i> , 2012, 96, 130-137.	1.9	35
34	Pharmacotherapy for hypertension in adults aged 18 to 59 years. <i>The Cochrane Library</i> , 2017, 2017, CD008276.	1.5	32
35	Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. <i>BMJ Open</i> , 2018, 8, e021108.	0.8	32
36	Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure. <i>Clinical Pharmacokinetics</i> , 2013, 52, 199-209.	1.6	31

#	ARTICLE	IF	CITATIONS
37	Efficacy of treating hypertension in women. <i>Journal of General Internal Medicine</i> , 1999, 14, 718-729.	1.3	30
38	No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2017, 12, e0171168.	1.1	30
39	Impaired baroreflex sensitivity and the risks of new-onset ambulatory hypertension, in an elderly population-based study. <i>International Journal of Cardiology</i> , 2013, 168, 4010-4014.	0.8	27
40	Metformin as firstline treatment for type 2 diabetes: are we sure?. <i>BMJ</i> , The, 2016, 352, h6748.	3.0	26
41	The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. <i>Journal of Clinical Epidemiology</i> , 2005, 58, 1042-1051.	2.4	25
42	Treatment of high blood pressure and gain in event-free life expectancy. <i>Vascular Health and Risk Management</i> , 2005, 1, 163-169.	1.0	25
43	Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 579-584.	1.0	23
44	Virtual Patients and Sensitivity Analysis of the Guyton Model of Blood Pressure Regulation: Towards Individualized Models of Whole-Body Physiology. <i>PLoS Computational Biology</i> , 2012, 8, e1002571.	1.5	23
45	New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 301-307.	2.4	22
46	The Global Risk Approach Should Be Better Applied in French Hypertensive Patients: A Comparison between Simulation and Observation Studies. <i>PLoS ONE</i> , 2011, 6, e17508.	1.1	20
47	Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 977-982.	2.4	19
48	SCORE should be preferred to Framingham to predict cardiovascular death in French population. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 609-615.	3.1	17
49	Physicians' Knowledge and Practice of Lung Cancer Screening: A Cross-Sectional Survey Comparing General Practitioners, Thoracic Oncologists, and Pulmonologists in France. <i>Clinical Lung Cancer</i> , 2013, 14, 574-580.	1.1	16
50	Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 24-32.	1.1	16
51	Towards personalized medicine: exploring the consequences of the effect model-based approach. <i>Personalized Medicine</i> , 2011, 8, 581-586.	0.8	15
52	Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals. <i>The Cochrane Library</i> , 2016, 2016, CD011745.	1.5	15
53	Different treatment benefits were estimated by clinical trials performed in adults compared with those performed in children. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1221-1231.	2.4	14
54	GLUcose COntrol Safety & Efficacy in type 2 Diabetes, a systematic review and NETwork meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0217701.	1.1	14

#	ARTICLE	IF	CITATIONS
55	Response to "inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993" The perspective of NIH clinical trialists. Contemporary Clinical Trials, 1995, 16, 286-288.	2.0	13
56	Pharmacotherapy for hypertension in women of different races. The Cochrane Library, 2000, , CD002146.	1.5	10
57	Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. BMC Medical Research Methodology, 2013, 13, 107.	1.4	10
58	Revising the ECRIN standard requirements for information technology and data management in clinical trials. Trials, 2013, 14, 97.	0.7	9
59	Anti-Trypanosoma cruzi Cross-Reactive Antibodies Detected at High Rate in Non-Exposed Individuals Living in Non-Endemic Regions: Seroprevalence and Association to Other Viral Serologies. PLoS ONE, 2013, 8, e74493.	1.1	9
60	Translational Research: Precision Medicine, Personalized Medicine, Targeted Therapies: Marketing or Science?. Therapie, 2015, 70, 11-19.	0.6	9
61	How do they add up? The interaction between the placebo and treatment effect: A systematic review. British Journal of Clinical Pharmacology, 2022, 88, 3638-3656.	1.1	9
62	Pharmacotherapy for mild hypertension. Sao Paulo Medical Journal, 2012, 130, 417-418.	0.4	8
63	Contribution of Modeling Approaches and Virtual Populations in Transposing the Results of Clinical Trials into Real Life and in Enlightening Public Health Decisions. Therapie, 2012, 67, 367-374.	0.6	7
64	Combined effect of renal function and serum potassium level in sudden cardiac death in aging hypertensive subjects. Hypertension Research, 2018, 41, 469-474.	1.5	7
65	Type 2 diabetes. Lancet, The, 2018, 391, 1261.	6.3	7
66	Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems. Clinical Chemistry and Laboratory Medicine, 2003, 41, 564-72.	1.4	6
67	Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial. Trials, 2012, 13, 231.	0.7	6
68	Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population. Journal of the Royal Society Interface, 2014, 11, 20140867.	1.5	6
69	The Calculation of a Confidence Interval on the Absolute Estimated Benefit for an Individual Patient. Journal of Biomedical Informatics, 1998, 31, 244-256.	0.7	5
70	How should therapeutic information be transferred to users?. Fundamental and Clinical Pharmacology, 2003, 17, 495-503.	1.0	5
71	The lower the better: Does simplicity lead to absurdity?. Journal of Hypertension, 2006, 24, 431-433.	0.3	5
72	How to Improve the Clinical Development Paradigm and its Division into Phases I, II and III. Therapie, 2011, 66, 331-334.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Pharmacoevidence Studies: what Levels of Evidence and how can They be Reached?. Therapie, 2013, 68, 247-252.	0.6	5
74	A sudden death risk score specifically for hypertension. Journal of Hypertension, 2017, 35, 2178-2184.	0.3	5
75	Investigation of one-stage meta-analysis methods for joint longitudinal and time-to-event data through simulation and real data application. Statistics in Medicine, 2019, 38, 247-268.	0.8	5
76	Editorial Comment "Secondary Prevention of Stroke: Beyond Meta-Analyses. Stroke, 2003, 34, 2748-2749.	1.0	4
77	The JIKEI trial. Lancet, The, 2007, 370, 1825-1826.	6.3	4
78	Clinically Relevant Efficacy of Insulin Therapy in Patients with Type 2 Diabetes. Therapie, 2013, 68, 415-417.	0.6	4
79	Meta-analysis of a continuous outcome combining individual patient data and aggregate data: a method based on simulated individual patient data. Research Synthesis Methods, 2014, 5, 322-351.	4.2	4
80	Protocol of GLUCOSE CONTROL Safety and Efficacy in type 2 Diabetes, a NETWORK meta-analysis: <scp>GLUCOSE DINET</scp> protocol "Rational and design. Fundamental and Clinical Pharmacology, 2017, 31, 258-264.	1.0	4
81	Investigation of 2-stage meta-analysis methods for joint longitudinal and time-to-event data through simulation and real data application. Statistics in Medicine, 2018, 37, 1227-1244.	0.8	4
82	Identification of responders to a therapy: an example of validation of a predictive model. European Journal of Epidemiology, 1999, 15, 559-567.	2.5	3
83	Antihypertensive treatment. Lancet, The, 1999, 354, 1028.	6.3	3
84	The IDEAL Study : Towards Personalized Drug Treatment of Hypertension. Therapie, 2012, 67, 195-204.	0.6	3
85	Farnesoid X Receptor Targeting for Hepatitis C: Study Protocol for a Proof-of-concept Trial. Therapie, 2012, 67, 423-427.	0.6	3
86	Is there excess mortality in women screened with mammography: a meta-analysis of non-breast cancer mortality. Trials, 2013, 14, 368.	0.7	3
87	Information et participation active des patients À l'aide d'une brochure interactive lors de la prescription d'antihypertenseurs en soins primaires. Sante Publique, 2013, Vol. 25, 193-201.	0.0	3
88	High Risk versus Proportional Benefit: Modelling Equitable Strategies in Cardiovascular Prevention. PLoS ONE, 2015, 10, e0140793.	1.1	3
89	How to measure the net benefit of treatment?. Therapie, 2017, 72, 51-61.	0.6	3
90	Risk reduction for stroke and coronary events. Lancet, The, 2002, 359, 1249.	6.3	2

#	ARTICLE	IF	CITATIONS
91	Do We Need to Assess the Effect of Treatment Withdrawal?. Stroke, 2007, 38, 2629-2630.	1.0	2
92	How to Improve Clinical Research Performances in France?. Therapie, 2008, 63, 297-300.	0.6	2
93	Comparison of crossover and parallelâ€group designs for the identification of a binary predictive biomarker of the treatment effect. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 59-64.	1.2	2
94	Are guidelines right to promote lifestyle interventions against hypertension?. Journal of Hypertension, 2004, 22, 2055-2056.	0.3	1
95	Another benefit from salt intake reduction?. Journal of Hypertension, 2004, 22, 1459-1460.	0.3	1
96	Sub-group analyses. Journal of Hypertension, 2004, 22, 467-469.	0.3	1
97	ModÃ©lisation et essais cliniques en pÃ©diatrie. Therapie, 2005, 60, 379-384.	0.6	1
98	Is legacy a myth or a reality? We should know, and we do not. Journal of Hypertension, 2015, 33, 2207-2209.	0.3	1
99	Comparative transcriptomic analysis between an artificially induced SIRS in healthy individuals and spontaneous sepsis. Comptes Rendus - Biologies, 2015, 338, 635-642.	0.1	1
100	Modelling and Clinical Trials in Paediatrics. Therapie, 2005, 60, 385-390.	0.6	0
101	Estimation of attributable burden of disease: authorsâ€™ reply. Journal of Hypertension, 2006, 24, 981-982.	0.3	0
102	Blood pressure lowering in the oldest old: a step toward abandoning arbitrary blood pressure targets. Journal of Hypertension, 2011, 29, 171-173.	0.3	0
103	Modeling the impact of cardiovascular prevention strategies. Journal of Hypertension, 2012, 30, 51-52.	0.3	0
104	Expected impact of a public health intervention in the presence of synergistic risk factors. Journal of Clinical Epidemiology, 2013, 66, 445-452.	2.4	0
105	Improving risk prediction performance for a better guidelines application. Journal of Hypertension, 2014, 32, 1192-1193.	0.3	0